Cannabinoids Show Promise Against Colon Cancer Cells in New Study
Cannabis compounds are already part of cancer care for some patients, mostly to help with symptoms such as nausea, pain, poor appetite, and anxiety. A newer question is harder and more important: could some cannabinoids act directly on cancer cells?
A recent lab study adds to that growing discussion. Researchers tested several phytocannabinoids from Cannabis sativa L. on SW-620 colon cancer cells, including cannabidiol, cannabigerol, and related derivatives. The results were early, cell-based, and not proof of a cancer treatment. Still, they point to a research path worth watching.
The study found that all tested cannabinoids showed cytotoxic effects at the lowest tested concentration of 3 μg/mL. Their half maximal inhibitory concentration, known as IC50, ranged from 3.90 to 8.24 μg/mL, depending on the compound. The team also confirmed cell damage in a 3D spheroid model, which better mimics how tumor cells grow in a dense structure.
This article is informational only and is not medical advice. Anyone using or considering cannabis-based products during cancer care should speak with an oncology professional, especially because of possible drug interactions and legal differences across states.
What the researchers tested
The study focused on phytocannabinoids, meaning plant-derived cannabinoids found in Cannabis sativa L. These compounds interact with many biological pathways, not only the well-known cannabinoid receptors.
The tested substances were:
Compound | Common name or description | Why it matters in this study |
CBD | Cannabidiol | A widely studied non-intoxicating cannabinoid |
CBD-HQ | Cannabidiol hydroquinone | A quinone-related derivative of CBD |
CBG | Cannabigerol | Often called a precursor cannabinoid because other cannabinoids derive from its acidic form |
CBG-A | Cannabigerolic acid | The acidic precursor related to CBG |
CBD + CBG | Combination treatment | Tested to see how the two compounds behaved together |
The target was the SW-620 colon cancer cell line. SW-620 is often used in colorectal cancer research because it gives scientists a controlled way to study how cancer cells respond to substances before moving to animal studies or clinical trials.
That point matters. Cell line studies are useful, but they are only an early step. A compound that kills cancer cells in a dish may not work the same way in the human body. It may be poorly absorbed, break down too quickly, affect healthy tissue, or interact with standard chemotherapy.
Still, this is where many cancer research questions begin.
How the study measured cancer cell death
The researchers used an MTT assay to test whether the cannabinoids reduced cell viability. In simple terms, this test estimates how many living, metabolically active cells remain after exposure to a compound.
Living cells convert the MTT reagent into a colored product. When fewer cells survive, the color signal drops. That change helps researchers estimate cytotoxicity.
The study reported two key findings from this test:
All tested cannabinoids were cytotoxic at 3 μg/mL
IC50 values ranged from 3.90 to 8.24 μg/mL
IC50 means the concentration needed to inhibit cell viability by 50%. A lower IC50 usually suggests stronger activity in that specific test system, although it does not automatically mean a compound is better or safer as a therapy.
The researchers did not stop with a flat layer of cells. They also used a 3D spheroidal cell culture, then stained the cells with calcein and propidium iodide.
These stains help distinguish live and damaged cells:
Calcein typically marks living cells.
Propidium iodide enters cells with damaged membranes, marking dead or dying cells.
Using 3D spheroids gives a more demanding model than a simple 2D cell layer. Tumor cells in the body grow in complex structures, where cells on the outside may have better access to nutrients and oxygen than cells inside. A spheroid cannot recreate a human tumor, but it adds useful complexity.
Why reactive oxygen species were measured
The study also looked at intracellular reactive oxygen species, often shortened to ROS. These are chemically reactive molecules that contain oxygen. Cells naturally produce ROS during metabolism, but high or poorly controlled ROS levels can damage DNA, proteins, and cell membranes.
Cancer biology makes ROS especially interesting. Tumor cells often live under stress and may have altered redox balance, meaning their systems for producing and neutralizing ROS can differ from normal cells. Some cancer treatments work partly by increasing oxidative stress until cancer cells cannot survive. Other compounds may protect cells from oxidative injury by lowering ROS.
In this study, the researchers measured ROS using a DCF-DA assay. This is a common method for estimating oxidative activity inside cells. The results showed clear differences among the cannabinoids.
CBG showed the lowest antioxidant activity among the tested cannabinoids. It reduced intracellular ROS by only 0.7% to 18%.
CBG-A showed the strongest reduction in ROS, lowering levels by 31% to 39%.
That is an important distinction. The cannabinoids did not behave as interchangeable versions of the same thing. Even closely related compounds, such as CBG and CBG-A, showed different effects in this assay. Chemical structure matters.
The ROS findings also raise a larger question for future research: are these compounds killing colon cancer cells through oxidative stress pathways, antioxidant activity, membrane disruption, apoptotic signaling, or a mix of mechanisms? The current findings suggest activity, but they do not fully explain the cause.
What makes CBG and CBG-A interesting
CBD gets most of the public attention, but this study highlights why lesser-known cannabinoids deserve closer study.
CBG is a non-intoxicating cannabinoid found in smaller amounts in many cannabis varieties. CBG-A is the acidic form connected to the biosynthesis of several major cannabinoids. In the plant, cannabinoids commonly appear first as acidic compounds. Heat, drying, or processing can convert them into neutral forms.
The contrast between CBG and CBG-A in the ROS assay is one of the more interesting parts of the study. CBG had the weakest antioxidant effect, while CBG-A produced the largest ROS reduction. That does not mean CBG-A is automatically the best anticancer candidate. It means it acted differently in this model.
Differences like this can shape future experiments. Researchers may ask:
Does CBG-A affect cancer cell metabolism differently from CBG?
Does the acidic form enter cells in the same way?
Are the observed effects tied to oxidative balance, cell membrane changes, or other pathways?
How do these compounds affect healthy colon cells at similar concentrations?
Do combinations with chemotherapy increase benefit or increase risk?
Those questions matter because a useful anticancer compound must do more than harm cancer cells in isolation. It must show selectivity, tolerability, and predictable behavior in living systems.
What the CBD and CBG combination may suggest
The study also tested CBD with CBG as a combination. Combination testing is common in cancer research because cancer cells often adapt to single-pathway pressure. Many standard cancer treatments use multiple agents to improve the chance of response or reduce resistance.
A CBD and CBG pairing is especially interesting because the compounds may influence overlapping but distinct targets. CBD has been studied for effects related to inflammation, apoptosis, cell signaling, and oxidative balance. CBG has attracted attention for possible effects on inflammation, microbial activity, and cell viability in certain models.
The abstract reports that the CBD + CBG combination was among the tested treatments and that all tested cannabinoids showed cytotoxicity at the lowest concentration. More detail would be needed to know whether the combination was additive, synergistic, or weaker than either compound alone.
That distinction is critical.
If two compounds are additive, their combined effect roughly matches the sum of their individual effects. If they are synergistic, the combination performs better than expected. If they are antagonistic, one compound may reduce the effect of the other.
Without that level of detail, the safest reading is simple: the combination showed activity in this model and deserves more careful testing.
Why these results are promising but not clinical proof
The phrase “anticancer potential” can be easy to overread. In this case, it means the cannabinoids showed activity against colon cancer cells under controlled lab conditions. It does not mean they cure colon cancer, shrink tumors in humans, or can replace chemotherapy, immunotherapy, radiation, surgery, or targeted treatment.
There are several reasons for caution.
Cell cultures are simplified models
Cells in a dish do not reflect the full biology of a person. Human tumors interact with blood vessels, immune cells, connective tissue, hormones, nutrients, and drug metabolism. A compound may look strong in vitro but fail later because it cannot reach the tumor at useful levels.
Concentration matters
The study used microgram-per-milliliter concentrations and found IC50 values between 3.90 and 8.24 μg/mL. To judge clinical relevance, researchers must learn whether those concentrations can be achieved safely in tissues, not just in a culture dish.
Cancer selectivity has to be shown
A compound that kills cancer cells may also harm healthy cells. Future work needs comparison with non-cancerous colon cells and other normal cell types. Selectivity is one of the key differences between a promising lab result and a drug candidate.
Cannabis products are not the same as purified compounds
The study tested selected cannabinoids under laboratory conditions. Over-the-counter cannabis products can vary in purity, dose, formulation, and cannabinoid profile. They may also contain THC or other ingredients that affect safety, cognition, or interactions with medication.
How this fits into cancer care today
Cannabinoid-based products already have a place in some areas of supportive oncology and palliative care. Some patients use cannabis-derived formulations to help manage pain, nausea, sleep problems, low appetite, or anxiety related to cancer and treatment.
That supportive use is different from using cannabinoids as anticancer agents.
For symptom care, doctors weigh patient comfort, side effects, local law, and interactions with other medications. For anticancer treatment, the evidence bar is much higher. Researchers need data from cell studies, animal models, pharmacology work, toxicology testing, and well-designed clinical trials.
This new work sits near the beginning of that path. It gives researchers signals to follow, especially around CBD, CBD-HQ, CBG, CBG-A, and CBD + CBG in colon cancer models.
The best next steps would likely include:
Testing these compounds against healthy colon cells
Comparing effects across multiple colorectal cancer cell lines
Studying dose and time dependence in more detail
Identifying the cell death pathway involved
Testing whether cannabinoids interact with standard colon cancer drugs
Moving into animal models only if safety and selectivity look reasonable
The takeaway from the study
This study adds useful early evidence that selected phytocannabinoids can reduce the viability of SW-620 colon cancer cells. CBD, CBD-HQ, CBG, CBG-A, and CBD + CBG all showed cytotoxic effects in the tested model, with IC50 values in the low microgram-per-milliliter range. The 3D spheroid results strengthened the finding, and the ROS data showed that the compounds do not all act alike.
The most striking contrast was between CBG and CBG-A. CBG had the weakest antioxidant effect, while CBG-A caused the largest reduction in intracellular ROS. That difference may help guide future work into how cannabinoid structure affects cancer cell behavior.
The practical message is careful optimism. Cannabinoids show promise against colon cancer cells in new study results, but the work remains preliminary. The findings support more research, not self-treatment or changes to a cancer care plan.
For now, cannabinoids should be viewed as a serious research subject and, in some cases, a supportive-care option under medical guidance. The next question is not whether these compounds look interesting in the lab. They do. The next question is whether they can be shown to work safely, selectively, and reliably in more complex cancer models.
Comments